Gland Pharma Reports Strong Q1 FY26 with 7% Revenue Growth; Cenexi Achieves Breakeven EBITDA
The significant increase in consolidated EBITDA (39% year-over-year) and the successful turnaround of Cenexi to breakeven profitability are crucial financial achievements. Strategic capacity expansions and new product launches in key markets also signal strong future growth potential and operational improvements.
The company reported strong consolidated revenue and EBITDA growth, driven by improved profitability in its base business and, notably, Cenexi achieving breakeven EBITDA after a challenging period. New product launches, pipeline expansion, and strategic capacity enhancements further contribute to a positive outlook.
Gland Pharma Limited announced its Q1 FY26 earnings, reporting a strong start to the financial year: * Consolidated revenue stood at ₹15,05.6 crore (INR 15,056 million), a 7% growth over Q1 last year. * Consolidated EBITDA reached ₹367.8 crore (INR 3,678 million), marking a strong 39% year-over-year increase, driven by EBITDA expansion in the base business and Cenexi's breakeven performance. * Consolidated EBITDA margin grew from 19% to 24% this quarter. * Cenexi, after a challenging period, achieved EBITDA breakeven in Q1 FY26 with a revenue of EUR 48 million and an EBITDA of EUR 0.9 million. Its gross margin improved to 80% from 78% last year. The turnaround is driven by a strategic shift towards higher-value offerings like prefilled syringes, lyophilised vials, and ophthalmic gels. * The U.S. market contributed ₹744.3 crore (INR 7,443 million) in revenues, making up 49% of the business. Nine new molecules were successfully launched in the U.S. during the quarter, including Epinephrine, Acetaminophen Bags, and three new strengths of Vancomycin. * Other regulated markets (Europe, Canada, Australia, New Zealand) grew 34% year-on-year, contributing 27% of total revenue. * The Rest of the World market contributed ₹297.8 crore (INR 2,978 million), representing 20% of revenue, with a modest 5% increase. * The Indian market generated ₹59.4 crore (INR 594 million), accounting for 4% of Q1 FY26 revenue. * Total R&D expenditure for Q1 FY26 was ₹46 crore (INR 460 million), which is 4.4% of the base business revenue. The company filed one product and received nine new approvals during the quarter, alongside 1,761 global registrations. * Gland Pharma launched nine new products in the U.S. and filed one RTU infusion bag, bringing the total to 20 such products filed in the U.S. (14 approved). An additional 10 RTU bag products are under development, addressing a market opportunity of approximately $760 million in the U.S. * In complex injectables, six products have been launched, with three more in line for approval. * The co-development model now comprises 15 products, including seven 505(b)(2) submissions and eight ANDAs, aligned to high-potential therapeutic areas. * The GLP-1 strategy gained momentum with the launch of Liraglutide in the U.K. and Australian markets. Pen and cartridge capacity is aggressively increasing from 40 million units to over 140 million units, with the Factory Acceptance Test scheduled for completion by September 25. * Management Comment: Mr. Srinivas Sadu, Executive Chairman, stated that the year began on a positive note, driven by improved profitability margins in Gland's base business and the encouraging turnaround of Cenexi to breakeven EBITDA. He expressed confidence that strategic actions will create a meaningful positive impact, supporting long-term success. Mr. Shyamakant Giri, CEO, affirmed that Gland's base business met expectations and Cenexi achieved breakeven EBITDA, highlighting that R&D remains a cornerstone for future growth and profitability.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.